Literature DB >> 10800258

Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability.

G J Lycklama à Nijeholt1, J A Castelijns, R H Lazeron, J H van Waesberghe, C H Polman, B M Uitdehaag, F Barkhof.   

Abstract

The authors compare the spinal cord magnetization transfer ratio (MTR) of multiple sclerosis (MS) patients to healthy volunteers, relate MTR to spinal cord atrophy, and relate these and other magnetic resonance (MR) imaging parameters to disability. Sixty-five patients with MS (14 relapsing remitting [RR], 34 secondary progressive [SP], and 17 primary progressive [PP] MS), and 9 healthy volunteers were studied using MR at 1.0 T. Disability of the patients was assessed using the expanded disability status scale (EDSS). Magnetic resonance parameters were upper spinal cord MTR, number of focal spinal lesions, presence of diffuse abnormalities, and spinal cord cross-sectional area (CSA). Correlations were assessed using Spearman's rank correlation coefficient (r). Magnetization transfer ratio was higher in the controls (median, 33%; range, 30%-38%) than in patients with MS (median, 30%; range, 16-36; p < 0.05). In patients with MS EDSS correlated with spinal cord MTR, albeit weakly (r = -0.25, p < 0.05). Correlation between EDSS and spinal cord CSA was better (SRCC = -0.40, p < 0.01). No correlation was found between MTR and CSA (r = 0.1, p = 0.4). Combining MTR with spinal cord CSA improved correlation with EDSS (r = -0.46, p < 0.001), suggesting an independent correlation between disability and these 2 MR parameters. Expanded disability status scale scores were higher in patients who had diffuse spinal cord abnormality regardless of focal lesions (median, 6; range, 1.5-7.5) than in patients without diffuse abnormalities (median, 3.5; range, 0-8; p < 0.01). CSA was lower in patients with diffuse spinal cord abnormality (median, 62; range, 46-89 mm2) than in patients without diffuse abnormalities (median, 73; range, 47-89 mm2; p < 0.01). MTR was slightly lower in patients with diffuse spinal cord abnormalities (median, 29; range, 21%-33%) than in patients without diffuse abnormalities (median, 31; range, 16-36; t-test, p < 0.05).

Entities:  

Mesh:

Year:  2000        PMID: 10800258     DOI: 10.1111/jon200010267

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  9 in total

Review 1.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 2.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

Review 3.  Brain and spinal cord atrophy in multiple sclerosis: role as a surrogate measure of disease progression.

Authors:  J H Simon
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.

Authors:  Allan R Martin; Izabela Aleksanderek; Julien Cohen-Adad; Zenovia Tarmohamed; Lindsay Tetreault; Nathaniel Smith; David W Cadotte; Adrian Crawley; Howard Ginsberg; David J Mikulis; Michael G Fehlings
Journal:  Neuroimage Clin       Date:  2015-12-04       Impact factor: 4.881

5.  Chemical exchange saturation transfer of the cervical spinal cord at 7 T.

Authors:  Adrienne N Dula; Siddharama Pawate; Lindsey M Dethrage; Benjamin N Conrad; Blake E Dewey; Robert L Barry; Seth A Smith
Journal:  NMR Biomed       Date:  2016-07-26       Impact factor: 4.044

Review 6.  Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review.

Authors:  Malgorzata Siger
Journal:  Clin Neuroradiol       Date:  2022-03-08       Impact factor: 3.156

7.  Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS".

Authors:  Antje Bischof; Nico Papinutto; Anisha Keshavan; Anand Rajesh; Gina Kirkish; Xinheng Zhang; Jacob M Mallott; Carlo Asteggiano; Simone Sacco; Tristan J Gundel; Chao Zhao; William A Stern; Eduardo Caverzasi; Yifan Zhou; Refujia Gomez; Nicholas R Ragan; Adam Santaniello; Alyssa H Zhu; Jeremy Juwono; Carolyn J Bevan; Riley M Bove; Elizabeth Crabtree-Hartman; Jeffrey M Gelfand; Douglas S Goodin; Jennifer S Graves; Ari J Green; Jorge R Oksenberg; Emmanuelle Waubant; Michael R Wilson; Scott S Zamvil; Bruce A Cree; Stephen L Hauser; Roland G Henry
Journal:  Ann Neurol       Date:  2022-03-26       Impact factor: 11.274

8.  Gut dysfunction in patients with multiple sclerosis and the role of spinal cord involvement in the disease.

Authors:  Giuseppe Preziosi; Dimitri A Raptis; Amanda Raeburn; Kumaran Thiruppathy; Jalesh Panicker; Anton Emmanuel
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 2.566

9.  Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.

Authors:  Lisa Eunyoung Lee; Irene M Vavasour; Adam Dvorak; Hanwen Liu; Shawna Abel; Poljanka Johnson; Stephen Ristow; Shelly Au; Cornelia Laule; Roger Tam; David Kb Li; Helen Cross; Nathalie Ackermans; Alice J Schabas; Jillian Chan; Ana-Luiza Sayao; Virginia Devonshire; Robert Carruthers; Anthony Traboulsee; Shannon Kolind
Journal:  Mult Scler       Date:  2021-03-22       Impact factor: 6.312

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.